# Who are Illumina's customers? Who does Illumina earn revenue from?
Canonical: https://valuechain.wiki/illumina · Facet: customers · Updated: 2026-09-11T12:41:32.258571+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Illumina's confirmed revenue counterparties include Abbott Laboratories, Tempus AI plus 2 undisclosed/aggregate relationships. Per the valuechain.wiki graph: 4 revenue edges, backed by 7 dated sources, 4 of them primary filings (as of 2026-09-11).

### 연구·제약·진단 (시퀀싱·소모품) (high)
- metric: Revenue $4.3B · FY2025 · FY2025 revenue (-0.7%); 2026 guidance $4.5-4.6B
- note: Supplies sequencers and consumables to research, pharma and diagnostics (sequencing 92% of revenue) — the core revenue source where the installed base drives recurring consumable demand.
- [mentions] consensus (via MarketBeat) (EN, research, published 2026-06-01) https://www.marketbeat.com/stocks/NASDAQ/ILMN/forecast/: "Analyst consensus Hold, average target ~$124 (17 analysts), range $80-170."
- [confirms] SEC EDGAR (EN, filing, published 2026-02-01) https://www.sec.gov/Archives/edgar/data/0001110803/000111080326000024/ilmn-20251228.htm: "Sequencers and consumables to research, pharma and diagnostics (sequencing 92%)."
- [confirms] Illumina (EN, news, published 2026-01-01) https://emea.illumina.com/company/news-center/press-releases/2026/fda84c92-b4b3-4691-a402-35555abe8605.html: "Sequencers and consumables to research, pharma and diagnostics (sequencing 92%)."
- [mentions] PharmNews (KO, news, published 2023-05-16) https://www.pharmnews.com/news/articleView.html?idxno=223717: "In 2023 Illumina completed certification of the high-throughput IVD clinical sequencer NovaSeq 6000Dx for domestic clinical labs, broadening access and lowering cost, which supports sequencer demand in the research and diagnostics market."

### 애보트 (high)  → /abbott-laboratories.md
- note: Illumina supplies the sequencing platform and instruments used by Abbott's acquired Exact Sciences business for its OncoExTra, MRD and MCED tests. Equipment and reagent sales are not disclosed.
- [mentions] SEC EDGAR (EN, filing, published 2026-03-23) https://www.sec.gov/Archives/edgar/data/1800/000110465926033079/tm268709d2_8k.htm: "Abbott completed the acquisition of Exact Sciences Corporation."
- [confirms] SEC EDGAR (EN, filing, published 2026-02-13) https://www.sec.gov/Archives/edgar/data/1124140/000112414026000011/exas-20251231.htm: "our OncoExTra test is currently only validated to be performed on Illumina's sequencing platform"

### 바이오AI·데이터 (BioInsight·ICA) (mid)
- note: AI drug-discovery data via BioInsight and cloud analytics.
- [confirms] Illumina (EN, news, published 2026-01-01) https://emea.illumina.com/company/news-center/press-releases/2026/fda84c92-b4b3-4691-a402-35555abe8605.html: "AI drug-discovery data via BioInsight and cloud analytics."

### Tempus AI (mid)  → /tempus-ai.md
- note: Supplies sequencers and consumables to precision-oncology diagnostics firm Tempus — a relationship where rising diagnostic throughput drives recurring consumable revenue.
- [confirms] Tempus (EN, filing, published 2026-02-24) https://www.tempus.com/news/pr/tempus-reports-fourth-quarter-and-full-year-2025-results/: "Sequencers and consumables to Tempus diagnostics."

Reverse side: https://valuechain.wiki/illumina/suppliers.md · Ripple: https://valuechain.wiki/illumina/ripple.md

---
Full node: https://valuechain.wiki/illumina.md · JSON: https://valuechain.wiki/illumina.json